Abstract 5112
Background
Most cancer patients are treated and followed up on an outpatient basis. A nursing led model of telephone care attention for cancer patients can be useful to improve the symptomatic control and the toxicity of the treatment. This model is being implemented in our hospital belonging to the Andorran Health Care Service. The specific aims of this study is to assess a nursing led model of telephone care attention for cancer patients in the course of treatment.
Methods
A descriptive prospective design has been used to analyze the telephone calls of cancer patients in treatment between outpatient appointments and the resolution capacity of oncology nurses. Telephone calls have been collected from October 2018 to March 2019 in a database. The variables analyzed using this database were: age, sex, type of tumor, type of treatment (oral or intravenous chemotherapy or immunotherapy), call reason and nursing resolution.
Results
49 telephone calls and 52 call reasons have been registered of 45 patients. On average, the patients were 58.1 (± 9.4) years old and 53% of them were male. Patients with colon and breast cancer were the most frequent, representing 20% and 16% respectively. 47% of patients were receiving intravenous chemotherapy, 36% oral chemotherapy and 18% immunotherapy. The call reasons were: 33% related to disease symptoms, 24 % related to toxicity, and 21 % related to treatment information and general issues. The most frequent reason for consultation was pain (23%) and the second was diarrhea (15%). Of the total telephone calls received, 92% were resolved by the nurse compared to 8% who required attention by a physician (p < 0.001).
Conclusions
Oncology nurse led model of telephone support for patients with cancer who attend outpatient treatment can improve symptomatic and toxicity management, reducing medical appointments and admissions to the Emergency Service.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hospital Nostra Senyora de Meritxell.
Funding
Has not received any funding.
Disclosure
G. Simó: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. C. Royo: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. E. Mahia: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. E. Baillés: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. S. Echevarria: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. A. Berenguer: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. S. Albiol: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell.
Resources from the same session
3212 - Multigene panel testing results for hereditary breast cancer in 1325 individuals: implications for gene selection and considerations for guidelines.
Presenter: Georgios Tsaousis
Session: Poster Display session 3
Resources:
Abstract
2591 - PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
Presenter: Julia Quintanilha
Session: Poster Display session 3
Resources:
Abstract
4377 - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): a retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials.
Presenter: Nuria Chic
Session: Poster Display session 3
Resources:
Abstract
3439 - Early on-treatment vs pre-treatment tumor transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer
Presenter: Sonia Pernas
Session: Poster Display session 3
Resources:
Abstract
2512 - AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)
Presenter: Claudia Cardone
Session: Poster Display session 3
Resources:
Abstract
4061 - Prevalence of EGFR mutations and its correlation with Egyptian patients’ human kinetics (PEEK Study)
Presenter: Adel Ibrahim
Session: Poster Display session 3
Resources:
Abstract
2547 - Evaluation of tumor microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)
Presenter: Sergio Rutella
Session: Poster Display session 3
Resources:
Abstract
4671 - Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt).
Presenter: Benoit Rousseau
Session: Poster Display session 3
Resources:
Abstract
3862 - Tumor mutation burden and microsatellite instability in colorectal cancer
Presenter: Francesca Fenizia
Session: Poster Display session 3
Resources:
Abstract
4614 - Predictors of Response to Checkpoint Inhibitors in Naïve and Ipilimumab-Refractory Melanoma
Presenter: Domenico Mallardo
Session: Poster Display session 3
Resources:
Abstract